Introduction
contact, most commonly in Africa, compared with 19% in 1992 [5] .
The HIV-1 epidemic in the UK, as well as some other European countries, is therefore increasingly heterogeneous, defined by origin and route of infection, as well as viral subtype. This complexity will also be reflected in differences in resistance patterns among antiretroviral treatment (ART)-naive patients, which is assumed to be transmitted HIV-1 drug resistance (TDR) driven by factors such as the availability and access of ART and use of prophylaxis against vertical transmission at the geographical source of infection. For these reasons, estimates of the prevalence of transmitted drug resistance in a country or at an international level might be meaningless without associated data on the likely origin of infection and the heterogeneity of the infected population.
Previous studies in the UK, mainly conducted in single centres, have demonstrated lower prevalence of transmitted drug resistance in patients infected with non-B virus compared with subtype B virus [6] [7] [8] [9] . Because the vast majority of HIV-1 transmissions within the UK occur among men who have sex with men, and who are primarily infected by subtype B virus [5] , these differences are to be expected. Nevertheless, estimates of TDR amongst non-B virus ranged from 2% to 10% [6] [7] [8] [9] . This is in contrast with the results of the World Health Organization surveillance in resource-limited settings [10] , which consistently show negligible TDR rates, as would be expected in countries in which treatment remains available to only a minority of infected individuals.
In this study, we undertook a detailed analysis of TDR in individuals migrating to the UK, using nonsubtype-B virus as a surrogate marker of infection acquired outside the UK if country of birth was not known. The analyses were based on data reported to the UK HIV Drug Resistance Database and linked to national HIV databases.
Methods
The UK HIV Drug Resistance Database is a central repository of genotypic resistance tests carried out as part of routine clinical care in the UK [8] . Demographic and clinical data were obtained via linkage to the UK Collaborative HIV Cohort study [11] , the UK Register of HIV Seroconverters [12] , the Survey of Prevalent HIV Infections Diagnosed [13] and the HIV and AIDS New Diagnoses national database. The first resistance test carried out in individuals who were reported as ART-naive and aged >16 at the time of sampling, up to the end of 2006, were identified. As routine resistance testing in ART-naive individuals was not always commonplace in the UK, samples taken prior to 2001 (when the British HIV Association guidelines [14] suggested consideration of resistance testing in ART-naive patients) were excluded in order to limit this testing bias.
Resistance was defined as the presence of ≥1 surveillance drug resistance mutation as proposed by Bennett et al. [15] , which is applicable to all subtypes. Subtype was defined using the REGA genotyping tool [16] . Non-B HIV-1 subtype was used as a surrogate marker of infection acquired outside the UK if country of birth was not known; individuals with non-B subtypes known to be born in the UK were excluded from the analyses (n=487, 10% of individuals with non-B subtype). Individuals with unclassifiable subtypes (who had unrecognized circulating recombinant forms [CRFs] or a poor quality test) were also excluded.
All analyses focused on patients with non-B virus; however, subtype B patients are included in some analyses to put the findings into context. In instances where small numbers in some subtype groups precluded reliable analysis, non-B subtypes were grouped as subtype C and subtype non-B non-C. Similarly, resistance tests on samples taken between 2001 and 2003 were grouped for some analyses.
Fisher's exact test was used for comparisons of proportions. Univariate and multivariate logistic regression was used to examine the association between demographic and clinical factors and the prevalence of TDR in non-B subtypes. Where demographic information was missing, a missing category was created, to avoid deletion of this information from the analyses. Region of origin was defined according to the World Health Organization regional office classification [17] . The closest CD4 + T-cell count measured within 6 months of the date of the sample was used for the analyses. Duration of infection, defined in relation to seroconversion, was not included as a predictor in the analyses because only 35 (0.8%) of the tests were performed during recent seroconversion. Similarly, year of arrival in the UK was unknown for 70% of patients, and therefore was also not included. For comparisons of individual mutations across subtypes, mutations that occurred at a frequency >5 within a subtype were identified within each subtype. A P-value of ≤0.01 was considered statistically significant for this analysis to take into account multiple testing. All analyses were carried out using Stata statistical software version 10.0 ( StataCorp LP, College Station, TX, USA).
Results
A total of 10,726 resistance tests carried out on ARTnaive individuals were available for analysis, of which 4,291 (40%) had non-B subtypes: 2,803 (26%) C, 463 (4%) A, 420 (4%) AG, 201 (2%) G, 167 (2%) AE, 122 (1%) D and 155 (1%) had rare but recognized CRF virus. Patients with non-B subtypes were predominantly Black African (n=2,469/3,026, 82% of those with available data), had acquired HIV-1 through heterosexual contact (n=2,874/3,100, 93% of those with available data) and approximately one-half had migrated to the UK from Southern Africa (n=1,314/2,430, 54% of those with available data; Table 1 ).
Prevalence of TDR across subtypes
The overall proportion of samples with resistance mutations in non-B subtypes was 4.6%, which varied across the subtypes from 3.0% in patients with subtype AE virus, to 3.3% D, 4.0% G, 4.5% AG, 4.6% C, 5.1% A and 7.0% in the patients with other rare CRF subtypes grouped together. The higher prevalence of TDR in this other category is puzzling and requires further investigation; however, the prevalence of TDR was lower in all non-B subtypes than subtype B (11.6%).
Prevalence of TDR over time 
Characteristics of resistance
Among tests showing resistance in non-B subtypes, overall, TDR was found to be confined to mutations associated with resistance to only one of the main drug classes (TDR was defined as the presence of ≥1 surveillance drug resistance mutation in the drug class); however, the proportion of patients with ≥1 mutation associated with >1 drug class was higher in patients with non-B non-C virus (32%) than subtype C (16%; P=0.01) and subtype B (13%; P<0.001; Table 2 ). Patterns of resistance also differed by drug class (Table 2) ; resistance only to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was more common in those with subtype C (47%) compared with subtype non-B non-C (29%; P=0.02) and subtype B (23%; P<0.001), and resistance only to nucleoside reverse transcriptase inhibitors (NRTIs) was less common in non-B subtypes (18%) compared to B (50%; P<0.001). Mutations associated with resistance to both NRTIs and NNRTIs were more likely in those with non-B non-C subtypes (26%) compared with subtypes C (14%; P=0.05) and B (6%; P<0.001). Triple-class resistance was uncommon in all subtypes: C (1%), non-B non-C (3%) and B (4%).
Resistance-associated mutations
There were no statistically significant differences in specific mutations between subtypes C and non-B non-C patients with resistance ( 
Predictors of TDR
Univariate and multivariate analyses showed that TDR was independently associated with calendar year of the time of sampling (P=0.001, 
Discussion
We describe a population of HIV-1-positive individuals with non-B subtypes, the majority of whom are presumed 2 (5) 6 (17) 136 (29) D67N 5 (12) 4 (11) 42 (9) T69D 1 (2) 3 (8) 14 (3) K70R 5 (12) 3 (8) 12 (3) M184V 10 (24) 13 (36) 25 (5) T215Y 3 (7) 3 (8) 17 (4 to have migrated to the UK. This group is largely of Black ethnicity from Africa, reflecting patterns of migration to the UK in the past decade. Our data suggest that the prevalence and characteristics of resistance in those reported as ART-naive are different between subtypes. Firstly, the prevalence of resistance was lower in those with non-B subtypes compared with subtype B virus, which were almost all likely to have been acquired in the UK. The long history of free access to ART in the UK, including use of mono-and dual-therapy before 1996 has led to a large pool of resistant virus, explaining the rates of transmission of resistance in those infected in the UK compared with those who have migrated from African countries. Improvements in treatment, including the use of newly available agents and better formulations of existing drugs, probably explain the reduction in rates of TDR in recent years in this population. Although non-B virus showed a lower prevalence of resistance overall, the downward time trend is at odds with the ongoing roll-out of ART in resource-limited settings. Epidemiological estimates suggest that the percentage of HIV-1 -positive women receiving ART for the prevention of mother-to-child transmission (PMTCT) in low and middle income countries has increased from 9% in 2004 to 33% in 2007. The numbers of those receiving ART for their own health has also increased 10-fold over this period, to 3 million individuals by the end of 2007 [19] . With this in mind, one might expect to see higher rates of TDR in those who migrated to the UK later in calendar time. There is a trend towards this in our dataset (DNC et al., data not shown), but migration dates were available for only a small number of individuals, precluding firm conclusions from being drawn.
Secondly, the precise mutational patterns differ between subtypes. In subtype B, resistance is mainly within the NRTI class, whereas in subtype C, NNRTI resistance accounts for most of the resistance seen. This might be explained by treatment practice in the country of origin of the individuals tested, as well as more limited monitoring strategies, which would encourage higher-level resistance to emerge in those on treatment [20] . It is well known that the use of single-dose nevirapine for PMTCT of HIV-1 leads to NNRTI resistance in the majority of those who receive it [21, 22] . It is possible that this also contributes to the pool of transmissible NNRTI resistance in resource-limited settings, where single-dose nevirapine is widespread. In addition, 62% of patients with non-B subtype and NNRTI resistance only were women, compared with only 3% of subtype B patients with NNRTI resistance, in our study. However, even within the NRTI class, differences were observed, most notably a higher prevalence of M184V in non-B virus. This mutation is rarely observed in transmitted viruses in primary infection cohorts, in which prior therapy can be excluded, most likely because of a rapid rate of reversion to wild type after transmission [23] . Conversely, we found lower prevalence of 215 variants in non-B virus, a set of mutations that are more common in untreated than treated individuals [24, 25] . These two findings suggest that at least some of the individuals infected with non-B virus in our study might actually be ART-experienced. This interpretation is supported by a higher prevalence of two-class resistance in non-B compared with subtype B virus in our dataset, again, an unusual characteristic for TDR seen in seroconverters [26] . A recent study assessing resistance in adults initiating first-line ART in Zambia, South Africa and Kenya reported an overall prevalence of 5.5%, with NNRTI resistance being most prevalent (3.8%); however, the authors could not rule out that undisclosed PMTCT might have contributed to the high rates observed [27] .
This study has some limitations. The data comes from several national databases, and missing information precludes reliable investigation of some variables. In particular, country of origin was unknown for 43% of patients with non-B virus. However, among patients infected with non-B virus for whom country of origin was known, 83% were born overseas. Country of origin also might not necessarily be the same as the country of HIV-1 infection and some patients originating from outside the UK might have been infected after migration. However, a recent molecular phylodynamic analysis of patients with non-B virus in the UK showed a low rate of clustering (compared with patients with subtype B virus) suggesting that most infections were likely to have been acquired outside the UK [28] . The increase in the number of tests done year on year leads to the possibility of testing bias in earlier years, which we have tried to limit by restricting the data. It is reassuring that the sensitivity analyses looking only at resistance tests performed on samples taken between 2004 and 2006 reaches similar conclusions. The duration of infection at the time of sampling is unknown and might influence estimates of TDR over time, as well as the frequency of specific mutations. We also reiterate that we cannot rule out the possibility that some individuals might have had treatment exposure in their country of origin before migrating to the UK; therefore, the potential for misclassification of a patient as ART-naive must be considered when interpreting cohort and surveillance studies.
In conclusion, our data demonstrate the importance in considering the heterogeneity of the epidemic when trying to assess TDR. Not only the prevalence, but also the characteristics of drug resistance differ between viral subtypes in people reported as ART-naive. Our data suggest evidence of undisclosed prior therapy in some individuals; however, whatever the reason for this resistance, there remains a tangible risk of subsequent therapy being compromised.
